RB 6145

• CAT Number: I035457
• CAS Number: 129448-97-1
• Molecular Formula: C8H14Br2N4O3
• Molecular Weight: 374.03
• Purity: 98%
• Synonyms: RB 6145; RB-6145; RB6145
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 1H-Imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide
• InChI: InChI=1S/C8H13BrN4O3.BrH/c9-1-2-10-5-7(14)6-12-4-3-11-8(12)13(15)16;/h3-4,7,10,14H,1-2,5-6H2;1H
• InChIKey: XPBJPGMCFKYBBV-UHFFFAOYSA-N
• SMILES: OC(Cn1c([N+]([O-])=O)ncc1)CNCCBr.Br

RB 6145 is an anticancer drug.

Reference

1: Winters T, Sercel A, Suto C, Elliott W, Leopold W, Leopold J, Showalter H. Design and synthesis of 2-nitroimidazoles with variable alkylating and acylating functionality. Chem Pharm Bull (Tokyo). 2014;62(3):301-3. PubMed PMID: 24583786.
2: Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer. 2010 Jul 13;103(2):201-8. doi: 10.1038/sj.bjc.6605753. Epub 2010 Jun 29. PubMed PMID: 20588272; PubMed Central PMCID: PMC2906743.
3: Miller TJ, Schneider RJ, Miller JA, Martin BP, Al-Ubaidi MR, Agarwal N, Dethloff LA, Philbert MA. Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology. 2006 Jan;27(1):44-59. Epub 2005 Aug 24. PubMed PMID: 16125243.
4: Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res. 2005 Jun 1;11(11):4212-6. PubMed PMID: 15930359.
5: Miller TJ, Phelka AD, Tjalkens RB, Dethloff LA, Philbert MA. CI-1010 induced opening of the mitochondrial permeability transition pore precedes oxidative stress and apoptosis in SY5Y neuroblastoma cells. Brain Res. 2003 Feb 14;963(1-2):43-56. PubMed PMID: 12560110.
6: Olive PL, Banáth JP, Durand RE. The range of oxygenation in SiHa tumor xenografts. Radiat Res. 2002 Aug;158(2):159-66. PubMed PMID: 12105985.
7: Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 2002 Jul;9(14):946-54. PubMed PMID: 12085243.
8: Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol. 2000 Feb 15;163(1):50-9. PubMed PMID: 10662604.
9: Breider MA, Ulloa HM, Pegg DG, Gough AW. Nitro-imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. Toxicol Pathol. 1998 Sep-Oct;26(5):651-6. PubMed PMID: 9789952.
10: Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 1998 Aug;78(4):439-45. PubMed PMID: 9716024; PubMed Central PMCID: PMC2063102.
11: Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol. 1998 Mar-Apr;26(2):234-9. PubMed PMID: 9547861.
12: Bullen WW, Rossi DT, Hoffman KL, Suri A, Lathia CD. An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma. J Pharm Biomed Anal. 1997 Sep;16(1):47-55. PubMed PMID: 9447551.
13: Skarsgard LD, Wouters BG. Substructure in the cell survival response at low radiation dose: effect of different subpopulations. Int J Radiat Biol. 1997 Jun;71(6):737-49. PubMed PMID: 9246187.
14: Butler SA, Wood PJ, Cole S, Williams C, Adams GE, Stratford IJ. Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br J Cancer. 1997;76(4):438-44. PubMed PMID: 9275019; PubMed Central PMCID: PMC2227976.
15: Hay MP, Denny WA, Wilson WR. Nitroimidazole-based "extruded mustards’ designed as reductively activated hypoxia-selective cytotoxins. Anticancer Drug Des. 1996 Jul;11(5):383-402. PubMed PMID: 8765531.
16: Horsman MR, Chaplin DJ, Hill SA, Arnold S, Collingridge D, Radacic M, Wood PJ, Overgaard J. Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer Suppl. 1996 Jul;27:S168-71. PubMed PMID: 8763873; PubMed Central PMCID: PMC2150003.
17: Wilson WR, Denny WA, Pullen SM, Thompson KM, Li AE, Patterson LH, Lee HH. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br J Cancer Suppl. 1996 Jul;27:S43-7. PubMed PMID: 8763844; PubMed Central PMCID: PMC2149993.
18: Wood PJ, Horsman MR, Khalil AA, Steinberg F, Streffer C, Overgaard J, Stratford IJ, Adams GE. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour. Acta Oncol. 1996;35(8):989-94. PubMed PMID: 9023383.
19: Skarsgard LD, Acheson DK, Vinczan A, Wouters BG, Heinrichs BE, Loblaw DA, Minchinton AI, Chaplin DJ. Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake. Br J Cancer. 1995 Dec;72(6):1479-86. PubMed PMID: 8519663; PubMed Central PMCID: PMC2034082.
20: Moselen JW, Hay MP, Denny WA, Wilson WR. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res. 1995 Feb 1;55(3):574-80. PubMed PMID: 7834627.